



IFW

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q74855

Yoshinori SEKIGUCHI, et al.

Appln. No.: 10/812,075

Group Art Unit: 1624

Confirmation No.: 3021

Examiner: Cecilia M. JAISLE

Filed: March 30, 2004

For: NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE
DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE
THEREOF

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, along with a copy of the corresponding Communication from a Foreign Patent Office, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

The present Information Disclosure Statement is being filed after the later of three months from the application's filing date and the mailing date of the first Office Action on the merits, but before a Final Office Action, Notice of Allowance, or an action that otherwise closes prosecution in the application (whichever is earlier), and therefore Applicant is filing concurrently herewith a Statement Under 37 C.F.R. § 1.97(e). No fee under 37 C.F.R. § 1.17(p) is required.

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for foreign language documents, Applicant encloses herewith a copy of a Communication from a foreign patent office in a counterpart application citing such documents, together with an English-language version of at least that portion of the Communication indicating the degree of relevance found by the foreign patent office.

Applicant notes for the Examiner's convenience that WO 03/028641 and US 2007/0037836 are English counterparts of CN 1582281. Further, that WO 93/17017, WO 00/20358, WO 01/96295, WO 02/30890, and WO 02/30891, cited in the Chinese Office Action were previously submitted with the Information Disclosure Statement filed May 4, 2007. In addition, CN-A-1610669 and CN-A-1582281, also cited in the Chinese Office Action, correspond to WO 03/053933A and WO 2004/004726A, respectively, which were also submitted with the Information Disclosure Statement filed May 4, 2007.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

INFORMATION DISCLOSURE STATEMENT
U.S. Appln. No.: 10/812,075

Attorney Docket No.: Q74855

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.


Respectfully submitted,

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE


23373

CUSTOMER NUMBER



Susan J. Mack
Registration No. 30,951

Date: August 17, 2007



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08a (05-07)

Approved for use through 09/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

| | |
|------------------------|-----------------------------|
| Application Number | 10812075 |
| Filing Date | 2004-03-30 |
| First Named Inventor | Yoshinori SEKIGUCHI, et al. |
| Art Unit | 1624 |
| Examiner Name | Cecilia M. Jaisle |
| Attorney Docket Number | Q74855 |

U.S. PATENTS

| Examiner Initial* | Cite No | Patent Number | Kind Code ¹ | Issue Date | Name of Patentee or Applicant of cited Document | Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear |
|-------------------|---------|---------------|------------------------|------------|---|--|
| | 1 | | | | | |

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S. PATENT APPLICATION PUBLICATIONS

| Examiner Initial* | Cite No | Publication Number | Kind Code ¹ | Publication Date | Name of Patentee or Applicant of cited Document | Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear |
|-------------------|---------|--------------------|------------------------|------------------|---|--|
| | 1 | 20070037836 | A | 2007-02-15 | Sekiguchi Yoshinori, et al. | Corresponds to WO 03/028641 |

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

| Examiner Initial* | Cite No | Foreign Document Number ³ | Country Code ² j | Kind Code ⁴ | Publication Date | Name of Patentee or Applicant of cited Document | Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear | T ⁵ |
|-------------------|---------|--------------------------------------|-----------------------------|------------------------|------------------|---|--|--------------------------|
| | 1 | 03/028641 | WO | A2 | 2003-04-10 | Taisho Pharmaceutical Co., Ltd. | | <input type="checkbox"/> |
| | 2 | 1582281 | CN | A | 2003-04-10 | Taisho Pharmaceutical Co., | | <input type="checkbox"/> |

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q74855

Yoshinori SEKIGUCHI, et al.

Appln. No.: 10/812,075

Group Art Unit: 1624

Confirmation No.: 3021

Examiner: Cecilia M. JAISLE

Filed: March 30, 2004

For: NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE
DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE
THEREOF

STATEMENT UNDER 37 C.F.R. § 1.97(e)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

The undersigned hereby states, upon information and belief:

That each item of information contained in the Information Disclosure Statement filed
concurrently herewith was first cited in any communication from a foreign patent office in a
counterpart foreign application not more than three months prior to the filing of said Information
Disclosure Statement.

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

Respectfully submitted,


Susan J. Mack
Registration No. 30,951

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: August 17, 2007